NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $25,526.15 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This represents a 0.04 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded down $0.65 during trading on Friday, hitting $21.76. The company’s stock had a trading volume of 690,361 shares, compared to its average volume of 531,607. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of -8.37 and a beta of -0.04. NewAmsterdam Pharma has a 52 week low of $15.19 and a 52 week high of $27.29. The stock has a 50-day moving average price of $21.70 and a two-hundred day moving average price of $21.16.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $3.30 million. On average, equities analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors have recently added to or reduced their stakes in NAMS. FMR LLC raised its holdings in NewAmsterdam Pharma by 35.6% during the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after purchasing an additional 86,712 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in NewAmsterdam Pharma by 1,231.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after buying an additional 221,305 shares during the last quarter. Walleye Capital LLC bought a new position in NewAmsterdam Pharma during the third quarter worth $779,000. Bellevue Group AG acquired a new position in NewAmsterdam Pharma in the third quarter valued at $128,000. Finally, ArrowMark Colorado Holdings LLC boosted its position in NewAmsterdam Pharma by 19.5% during the third quarter. ArrowMark Colorado Holdings LLC now owns 354,975 shares of the company’s stock valued at $5,893,000 after acquiring an additional 57,806 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NAMS shares. HC Wainwright reissued a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Scotiabank upped their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Royal Bank of Canada restated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Finally, Needham & Company LLC dropped their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Buy” and a consensus price target of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.